Published in

Wiley, Chemical Biology & Drug Design, 5(98), p. 903-913, 2021

DOI: 10.1111/cbdd.13948

Links

Tools

Export citation

Search in Google Scholar

Glucosyl‐1,2,3‐triazoles derived from eugenol and analogues: Synthesis, anti‐Candida activity, and molecular modeling studies in CYP‐51

This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Orange circle
Postprint: archiving restricted
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

AbstractThis work describes the synthesis, anti‐Candida, and molecular modeling studies of eighteen new glucosyl‐1,2,3‐triazoles derived from eugenol and correlated phenols. The new compounds were characterized by combined Fourier Transform Infrared, 1H and 13C nuclear magnetic resonance and spectroscopy of high‐resolution mass spectrometry. The synthesized compounds did not show significant cytotoxicity against healthy fibroblast human cells (MCR‐5) providing interesting selectivity indexes (SI) to active compounds. Considering the antifungal activity, nine compounds showed anti‐Candida potential and the peracetylated triazoles 17 and 18 were the most promising ones. Eugenol derivative 17 was active against three species of Candida at 26.1–52.1 μM. This compound was four times more potent than fluconazole against Candida krusei and less toxic (SI > 6.6) against the MCR‐5 cells than fluconazole (SI > 3.3) considering this strain. Dihydroeugenol derivative 18 showed similar activity to 17 and was four times more potent and less toxic than fluconazole against C. krusei. The deacetylated glucosides and non‐glucosylated corresponding derivatives did not show considerable antifungal action, suggesting that the acetyl groups are essential for their anti‐Candida activity. Molecular docking coupled with molecular dynamics showed that 14α‐lanosterol demethylase is a feasible molecular target, since 17 and 18 could bind to this enzyme once deacetylated in vivo, thereby acting as prodrugs. Also, these studies demonstrated the importance of hydrophobic substituents at the phenyl ring.